TAE Life Sciences fetches $40 mln Series A in ARTIS Ventures-led round

TAE Life Sciences, a developer of treatments for difficult to treat cancers, has raised $40 million in Series A funding. ARTIS Ventures led the round.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!